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Purpose: Leber congenital amaurosis (LCA) is the most severe form of inherited retinal dystrophy, and invariably leads
to blindness. LCA is a genetically and clinically heterogenous disorder. Although more than nine genes have been found
to be associated with LCA, they only account for about half of LCA cases. We performed a comprehensive mutational
analysis on nine known genes in 20 unrelated patients to investigate the genetic cause of LCA in Koreans.
Methods: All exons and flanking regions of the nine genes (AIPL1, CRB1, CRX, GUCY2D, RDH12, RPE65, RPGRIP1,
LRAT, and TULP1) were analyzed by direct sequencing. We also screened our patients for the common CEP290: c.
2991+1655A>G mutation found in Caucasian.
Results: Six different mutations including four novel ones were identified in three patients (15.0%): one frameshift, one
nonsense, one splicing, and three missense mutations. These patients were compound heterozygotes and harbored two
different mutations in CRB1, RPE65, and RPGRIP1, respectively. We identified three novel unclassified missense variants
in RPGRIP1 of the three patients. These patients were heterozygous for each variant and did not have a large deletion or
duplication in the same gene.
Conclusions: This comprehensive mutational analysis shows marked genetic heterogeneity in Korean LCA patients and
reveals a mutation spectrum that differs from those previously reported. In turn, this suggests that a different strategy
should be used for the molecular diagnosis of LCA in Koreans.
Leber congenital amaurosis (LCA; OMIM 204000), is
the most severe form of all inherited retinal dystrophies, and
is  an  important  cause  of  congenital  blindness  in  many
countries [1,2]. Its incidence has been estimated at 2–3 per
100,000 live births, and it is known that LCA accounts for 5%
of all inherited retinal dystrophies, and for up to 20% of
children attending schools for the blind worldwide.
LCA  is  a  clinically  and  genetically  heterogenous
disorder. Early onset blindness during the first year of life
(especially  before  six  months),  ocular  features  like
oculodigital  signs  (eye  poking,  rubbing,  and  pressing),
sluggish  pupillary  reaction,  and  extinguished  or  severely
reduced ERG are accepted highly suggestive criteria, but none
of these are diagnostic for LCA [1]. In addition to ocular
symptoms, systemic symptoms such as neurodevelopmental
delay can be associated with LCA. However, some systemic
diseases,  such  as  Senior-Loken  syndrome,  Conorenal
syndrome,  and  Joubert  syndrome,  can  manifest  ocular
symptoms, which complicate the differential diagnosis [3,4].
Alternatively,  early-onset  retinal  dystrophies  like  retinitis
pigmentosa (RP; OMIM 268000) and cone-rod dystrophy
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(CRD; OMIM 600624) may have clinical features resembling
those of LCA.
Nine  genes,  i.e.,  GUCY2D  (LCA1),  RPE65  (LCA2),
AIPL1 (LCA4), RPGRIP1, LCA5 (LCA6), CRB1 (LCA7),
CRX (LCA8), RDH12, and CEP290 (LCA10) are generally
accepted to be implicated in LCA, and three additional genes
(TULP1,  LRAT,  and  IMPDH1)  and  two  loci  (LCA3  and
LCA9)  may  also  be  associated  with  the  disease  (RetNet,
Genetests). However, LCA may be associated with many
more  genes:  only  an  estimated  50%  of  cases  have  been
diagnosed by molecular methods even in large studies, and
about 130 genes are known to be implicated in inherited retinal
diseases [5]. Some genes related with LCA are involved in
other inherited retinal diseases, such as RP and CRD, and thus
these diseases may be viewed as a spectrum of genetically
related diseases [6,7].
The clinical and genetic heterogeneity of LCA hampers
its  routine  molecular  diagnosis.  The  establishment  of
phenotype-genotype correlations and the development of a
high-throughput screening method would offer a means of
overcoming these difficulties. The comprehensive mutational
analysis  is  required  to  both  establish  genotype-phenotype
correlations and determine mutation distribution patterns, but
few such studies have been conducted to date [5,8]. Moreover,
those results mainly came from Caucasian, so comprehensive
mutational  analysis  in  non-Caucasian  can  be  helpful  to
understand pathogenic mechanism of LCA. Here, we report
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1429the results of a comprehensive mutational analysis conducted
on nine known LCA genes in 20 Korean LCA patients.
METHODS
Subjects: A total of 20 unrelated patients were recruited from
the  ophthalmology  clinics  at  Seoul  National  University
Hospital and Seoul National University Bundang Hospital
from 1999 to 2007. The median age of patients at initial
diagnosis was 8 months (range 3 to 33) and male to female
ratio was 2:3. Informed consent was obtained from all patients
or  their  legal  guardians  for  the  provision  of  clinical
information  and  blood  samples.  All  patients  received  a
detailed ophthalmic examination including electroretinogram
and was diagnosed with LCA based on the following criteria,
suggested by De Laey [9]: early onset blindness or severe
visual  impairment  during  the  first  year  of  life  (especially
before  six  months),  with  oculodigital  signs  (eye  poking,
rubbing, and pressing); an extinguished or severely reduced
ERG; and the exclusion of other systemic diseases.
The mutational analysis included 170 healthy individuals
as a control for a 1% polymorphism [10].
Sequence analysis of nine genes—Genomic DNA was
immediately extracted from peripheral blood using Gentra
PureGene  DNA  isolation  kits  (Gentra  Systems,  Inc.
Minneapolis, MN). The full sequence of nine genes that have
been associated with LCA or an LCA-like phenotype were
analyzed,  i.e.,  seven  genes  associated  with  LCA:  AIPL1,
CRB1, CRX, GUCY2D, RDH12, RPE65, and RPGRIP1, and
two genes associated with an LCA-like phenotype: LRAT, and
TULP. PCR was performed on patient genomic DNA using
primers designed to flank the splice junctions of coding exons.
The  PCR  parameters  were  as  follows:  95  °C  for  5  min,
followed by 35 cycles of 95 °C for 30 s, 60 °C for 30 s, and
72  °C  for  1  min.  Amplified  products  were  sequenced
bidirectionally  on  an  ABI  Prism  3100  Genetic  Analyzer
(Applied Biosystems, Foster City, CA), then analyzed using
Sequencher software (Gene Codes Co, Ann Arbor, MI).
c.2991+1655A>G mutation of CEP290—In addition to
full sequencing of nine genes, we performed allele-specific
PCR. This was to determine whether c.2991+1655A>G, an
intronic mutation in CEP290 and described as one of the most
frequent  causes  of  LCA  in  a  Caucasian,  could  also  be  a
common cause in the Korean population [11].
Gene  dosage  analysis—In  the  case  of  a  single
heterozygote  with  one  mutation,  we  performed
semiquantitative PCR to exclude the possibility of a large
deletion or duplication in the gene concerned. Each exon of
RPGRIP1 and the reference gene, B2MG, were co-amplified
with fluorescence-labeled primers through 18 limited cycles.
Then labeled PCR products were analyzed on the ABI Prism
3100 Genetic Analyzer, and the heights of the peaks of interest
were measured with the ABI Prism Data Collection Software
(v2.0). Normalized gene dosage for each exon was determined
by using the following equation:
Gene dosage=   [Peak target (patient)/Peakreference(patient)]/
[Peaktarget(control)/Peakreference(control)]
Allele frequency in control subjects—To investigate
allele frequencies, we screened control subjects by denaturing
high-pressure liquid chromatography (dHPLC). DNA, pooled
from  three  control  subjects,  was  amplified.  Next,  PCR
products  were  denatured  for  10  min  at  95  °C  and  then
gradually reannealed by decreasing temperatures from 95 °C
to 25 °C over 30 min. PCR products were eluted at a flow rate
of 0.9 ml/min on the Wave 3500 (Transgenomics, Omaha,
NE). Pooled DNA samples displaying an abnormal profile
were analyzed by direct sequencing to determine the specific
genotype of each subject.
Information  from  amino  acids  and  proteins—
Generally, in genetic mutation studies such as the present
study,  it  is  critical  to  determine  whether  novel  missense
variations  are  likely  to  be  harmful  to  protein  function  or
structure.  However,  functional  analysis  is  not  always
available to investigate the effect of a missense variation on a
protein. We have predicted the functional effect of a novel
missense variation using information from the characteristics
of  the  amino  acids  substituted,  interspecies  amino  acid
conservation  using  ClustalW  [12],  and  protein  structural
information from Uniprot.
In-silico prediction of novel missense variation using
different software—We compared the aforedescribed results
with those obtained using three protein function prediction
software: Polyphen [13], SIFT [14], and PMut [15]. All three
prediction software packages have been previously applied to
various disease-gene models [16-18].
RESULTS
Mutations:  We  identified  six  different  mutations  in  three
patients (15%), in CRB1 (5%), RPE65 (5%), and RPGRIP1
(5%; Table 1). No homozygous mutations were found in this
study.  All  three  patients  had  a  compound  heterozygous
mutation: c.271C>T (R91W) and c.858+1G>T (IVS8+1G>T)
in  RPE65  (case  5);  c.1892A>T  (H631P)  and  c.
3560_3566delAAGGCCG  in  RPGRIP1  (case  13);  and  c.
998G>A (G333D) and c.1576C>T (R526X) in CRB1 (case
17).
All six mutations uniquely occurred in families. Two
mutations in RPGRIP1 and two in CRB1 were novel, whereas
two mutations found in RPE65 have been reported previously
[19,20]. Two of four novel mutations produced null alleles: c.
3560_3566delAAGGCCG  (premature  protein  translation
termination  at  codon  1195)  and  c.1576C>T  (R526X).
Segregation of disease alleles was confirmed in case 13, for
whom DNA samples from both parents were available. We
classified  the  other  two  novel  missense  variations  as
pathogenic mutations because each was accompanied by a
null allele and was predicted to be harmful to protein structure
or function on prediction analysis.
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.Case 13, who had novel mutations in RPGRIP1, had a
history  of  photophobia  and  displayed  peripheral
hyperpigmentation in the retina. The posterior pole and disc
had a relatively normal appearance. Visual acuity was 20/500
OD and 20/500 OS. Case 17, who had novel mutations in
CRB1,  had  a  history  of  night  blindness  and  diffuse
hyperpigmentation in the retina, with vascular attenuation.
Visual acuity was 20/300 OD and hand motion OS. These
findings were similar to the genotype-phenotype correlations
suggested by Hanein et al. [5].
The two novel missense variations were not found among
170  control  subjects,  which  showed  allele  frequencies  of
<0.01 for all variations (Table 1). We analyzed amino acid
conservation for the genes concerned in Homo sapiens, Pan
troglodytes, Bos taurus, Canis familiaris, Mus musculus, and
Rattus  norvegicus.  Two  missense  variations  were  well
conserved  across  these  species  and  homologous  proteins
(Figure 1). H631P was located in the structurally important
C2 domain [21] and G333D was located in an epidermal
growth  factor  (EGF)-like  domain,  near  a  disulfide  bond
between  codon  327  and  336.  Moreover,  all  of  the
aforedescribed substituted amino acids were quite different
from  the  original  amino  acids  in  terms  of  their
physicochemical  characteristics.  The  BLOSUM62  [22]
matrix score was also negative for two missense variations,
which  supports  their  pathogenic  potential,  and  Polyphen,
SIFT, and PMut produced similar results. These variations
were predicted to be pathogenic by two or more of these
prediction  tools.  Therefore,  we  considered  c.1892A>T
(H631P) in RPGRIP1, and c.998G>A (G333D) in CRB1 as
pathogenic mutations (Table 1).
Unclassified missense variants: Interestingly, we identified
three novel missense variations only in RPGRIP1: c.1295C>T
(S432F), c.1802C>G (S601W), and c.3170A>T (H1057L).
All patients with these missense variants were heterozygous
for each variant and a second mutation, and the presence of a
large deletion or duplication in the same gene were excluded
in these patients.
Three  variants  were  located  in  structurally  important
regions: S432F in the coiled-coil region, S601W in the C2
domain, and H1057L in the RPGR interacting domain. All
substitutions represented negative BLOSUM62 [22] matrix
score and were predicted to be pathogenic using the prediction
software  packages.  c.1295C>T  (S432F)  and  c.3170A>T
Figure  1.  Multiple  alignments  using
ClustalW and amino acid conservation
of  four  novel  missense  sequence
variations  identified  in  RPGRIP1:  c.
1295C>T  (S432F),  c.1802C>G
(S601W), c.1892A>T (H631P), and c.
3170A>T (H1057L). The first six amino
acid  sequences  in  each  segment
represent RPGRIP1 proteins of several
species, and the last four denoted with
(L)  represent  RPGRIP1-like  proteins.
Alignment results show that histidine at
codon  631  is  highly  conserved,  but
amino acids at codon 432, 601, and 1057
are poorly conserved.
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.(H1057L)  were  also  found  in  control  subjects  (Table  1).
Amino acid conservation at these positions was restricted to
some  species  (Figure  1),  suggesting  a  possibility  of  rare
polymorphism. c.1802C>G (S601W) was not found among
170 control subjects, although serine at codon 601 was not
well  conserved  among  different  species.  Therefore,  it  is
uncertain at this point whether c.1802C>G (S601W) is a rare
polymorphism or not.
Polymorphisms: In addition to the aforedescribed mutations
and  unclassified  variants,  we  observed  82  sequence
variations, of which 24 were located in exons and 58 in introns
(Table 2). The following three among 13 nonsynonymous
sequence  variations  were  novel:  c.2809G>A  (A937T)  in
CRB1, c.460A>G (T154A) in CRX, and c.783G>C (K261N)
in TULP1. A nonsynonmous sequence variation in CRB1, c.
2809G>A (A937T), was found in EGF-like domain 14, but it
was felt that this substitution was unlikely to impair protein
function  because  the  two  amino  acids  have  similar
physicochemical  characteristics.  All  three  software  tools
predicted  that  this  substitution  would  not  be  pathological
(Polyphen score of 0.428, SIFT score of 0.70, and PMut score
of 0.22). A nonsynonymous sequence variation in CRX, c.
460A>G (T154A) was also considered to be a polymorphic
sequence variation, because it is located outside the homeobox
domain  (35–101),  even  though  the  amino  acid  is  well
conserved. The three programs concurred that substitution is
unlikely to be pathologic (Polyphen score of 1.449, SIFT
[score of 0.26, and PMut score of 0.25). We did not find these
two  nonsynonymous  mutations  in  control  subjects,  and
therefore,  we  consider  them  rare  polymorphic  sequence
variations.  Finally,  c.783G>C  (K261N)  in  TULP1  was
frequently found in controls and patients.
We identified 58 intronic sequence variations in patients.
Intronic sequence variations flanking exon-intron boundaries
potentially capable of affecting exon splicing were as follows:
IVS2–14G>A  (allele  frequency,  0.03)  and  IVS5+18G>A
(allele frequency, 0.08) in AIPL1, and IVS2–13insT (allele
frequency,  0.08)  in  the  RDH12,  IVS2+18G>A  (allele
frequency, 0.08) in TULP1. However, we could not exclude
the possibility of splice disruption because we had failed to
recover the mRNA of concerned genes from peripheral blood
cells.
DISCUSSION
The mutation spectrum revealed in this study shows marked
genetic heterogeneity as well as different features from those
found in previous studies. In previous studies except ones
about  CEP290,  mutation  in  GUCY2D  was  most  common
(6%–21%), followed by CRB1, and RPE65, and the mutations
in RPGRIP1 accounted for less than 5% of all mutations [5,
7,8]. In our series, however, neither GUCY2D mutation nor
the intronic mutation, CEP290: c.2991+1665A>G was never
found [11]. In addition, the molecular detection rate was only
15% in this study, despite the inclusion of all nine known
genes, which is substantially lower than about 50% in other
large  studies.  Finally,  all  three  patients  harboring  two
mutations were compound heterozygotes, and all mutations
were restricted to families. This mutation spectrum suggests
that there might be no founder mutation, but rather that Korean
LCA  patients  show  marked  genetic  heterogeneity.  Our
findings  also  mean  that  it  will  be  difficult  to  develop  an
effective  screening  method,  and  that  a  search  for  new
candidate genes is warranted.
We  identified  three  novel  unclassified  variants  in
RPGRIP1.  A  possibility  of  pathogenic  mutation  remains
questionable; patients heterozygous for each variant do not
have a second mutation in the same gene, and functional
effects of such a substitution is controversial on predictions.
However, a large gene rearrangement or hidden mutation in
the  unscreened  region  could  be  complicated  with  these
variants observed in this study. We excluded the possibilities
of a large deletion or duplication using the gene dosage test,
but we could not exclude the possibility of a hidden splice
mutation because we had failed to recover the mRNA of
RPGRIP1 from peripheral blood cells. Mutation in another
gene may have an additive effect to these variants of unknown
significance. Interestingly, all these heterozygous missense
variations  were  in  RPGRIP1.  Because  RPGRIP1  protein
closely interacts with RPGR in the retinal pigment epithelium
and  RPGR  causes  severe  X-linked  RP,  a  digenism  by
RPGRIP1  and  RPGR  may  be  a  potential  cause  of  many
heterozygotes in this study.
The locus heterogeneity and allelic heterogeneity of LCA
necessitate the development of an effective screening tool,
such  as  a  microarray,  or  the  establishment  of  genotype-
phenotype correlations, and is also require comprehensive
mutational analysis in this field. This study is not only one of
a few reports of comprehensive mutational analysis but to our
knowledge is also the most comprehensive one in the non-
Caucasian.  In  summary,  our  study  shows  marked  genetic
heterogeneity in Korean LCA patients and reveals a mutation
spectrum  that  differs  from  those  previously  reported,
indicating a different strategy should be used for the molecular
diagnosis of LCA in the Korean population.
ACKNOWLEDGMENTS
This study was supported by a grant from the Korea Health
21 R&D Project, Ministry of Health & Welfare, Republic of
Korea (A050488).
REFERENCES
1. Fazzi E, Signorini SG, Scelsa B, Bova SM, Lanzi G. Leber's
congenital amaurosis: an update. Eur J Paediatr Neurol 2003;
7:13-22. [PMID: 12615170]
2. Koenekoop RK. An overview of Leber congenital amaurosis: a
model  to  understand  human  retinal  development.  Surv
Ophthalmol 2004; 49:379-98. [PMID: 15231395]
3. Fazzi E, Signorini SG, Uggetti C, Bianchi PE, Lanners J, Lanzi
G.  Towards  improved  clinical  characterization  of  Leber
Molecular Vision 2008; 14:1429-1436 <http://www.molvis.org/molvis/v14/a171> © 2008 Molecular Vision
1434congenital amaurosis: neurological and systemic findings.
Am J Med Genet A 2005; 132A:13-9. [PMID: 15580639]
4. Casteels I, Spileers W, Demaerel P, Casaer P, De Cock P,
Dralands  L,  Missotten  L.  Leber  congenital  amaurosis–
differential  diagnosis,  ophthalmological  and
neuroradiological report of 18 patients. Neuropediatrics 1996;
27:189-93. [PMID: 8892367]
5. Hanein S, Perrault I, Gerber S, Tanguy G, Barbet F, Ducroq D,
Calvas P, Dollfus H, Hamel C, Lopponen T, Munier F, Santos
L, Shalev S, Zafeiriou D, Dufier JL, Munnich A, Rozet JM,
Kaplan J. Leber congenital amaurosis: comprehensive survey
of  the  genetic  heterogeneity,  refinement  of  the  clinical
definition, and genotype-phenotype correlations as a strategy
for  molecular  diagnosis.  Hum  Mutat  2004;  23:306-17.
[PMID: 15024725]
6. Allikmets R. Leber congenital amaurosis: a genetic paradigm.
Ophthalmic Genet 2004; 25:67-79. [PMID: 15370538]
7. Cremers FP, van den Hurk JA, den Hollander AI. Molecular
genetics  of  Leber  congenital  amaurosis.  Hum  Mol  Genet
2002; 11:1169-76. [PMID: 12015276]
8. Zernant J, Külm M, Dharmaraj S, den Hollander AI, Perrault I,
Preising MN, Lorenz B, Kaplan J, Cremers FP, Maumenee I,
Koenekoop  RK,  Allikmets  R.  Genotyping  microarray
(disease chip) for Leber congenital amaurosis: detection of
modifier  alleles.  Invest  Ophthalmol  Vis  Sci  2005;
46:3052-9. [PMID: 16123401]
9. De  Laey  JJ.  Leber's  congenital  amaurosis.  Bull  Soc  Belge
Ophtalmol 1991; 241:41-50. [PMID: 1840995]
10. Collins  JS,  Schwartz  CE.  Detecting  polymorphisms  and
mutations  in  candidate  genes.  Am  J  Hum  Genet  2002;
71:1251-2. [PMID: 12452182]
11. den Hollander AI, Koenekoop RK, Yzer S, Lopez I, Arends ML,
Voesenek  KE,  Zonneveld  MN,  Strom  TM,  Meitinger  T,
Brunner HG, Hoyng CB, van den Born LI, Rohrschneider K,
Cremers FP. Mutations in the CEP290 (NPHP6) gene are a
frequent cause of Leber congenital amaurosis. Am J Hum
Genet 2006; 79:556-61. [PMID: 16909394]
12. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins
DG, Thompson JD. Multiple sequence alignment with the
Clustal  series  of  programs.  Nucleic  Acids  Res  2003;
31:3497-500. [PMID: 12824352]
13. Ramensky V, Bork P, Sunyaev S. Human non-synonymous
SNPs:  server  and  survey.  Nucleic  Acids  Res  2002;
30:3894-900. [PMID: 12202775]
14. Ng  PC,  Henikoff  S.  Predicting  deleterious  amino  acid
substitutions.  Genome  Res  2001;  11:863-74.  [PMID:
11337480]
15. Ferrer-Costa  C,  Orozco  M,  de  la  Cruz  X.  Sequence-based
prediction  of  pathological  mutations.  Proteins  2004;
57:811-9. [PMID: 15390262]
16. Mátyás G, Arnold E, Carrel T, Baumgartner D, Boileau C,
Berger W, Steinmann B. Identification and in silico analyses
of  novel  TGFBR1  and  TGFBR2  mutations  in  Marfan
syndrome-related  disorders.  Hum  Mutat  2006;  27:760-9.
[PMID: 16791849]
17. Ng  PC,  Henikoff  S.  Predicting  the  effects  of  amino  Acid
substitutions on protein function. Annu Rev Genomics Hum
Genet 2006; 7:61-80. [PMID: 16824020]
18. Schaeffeler  E,  Eichelbaum  M,  Reinisch  W,  Zanger  UM,
Schwab  M.  Three  novel  thiopurine  S-methyltransferase
allelic  variants  (TPMT*20,  *21,  *22)  -  association  with
decreased  enzyme  function.  Hum  Mutat  2006;  27:976.
[PMID: 16917910]
19. Gu SM, Thompson DA, Srikumari CR, Lorenz B, Finckh U,
Nicoletti A, Murthy KR, Rathmann M, Kumaramanickavel
G, Denton MJ, Gal A. Mutations in RPE65 cause autosomal
recessive childhood-onset severe retinal dystrophy. Nat Genet
1997; 17:194-7. [PMID: 9326941]
20. Thompson  DA,  Gyürüs  P,  Fleischer  LL,  Bingham  EL,
McHenry  CL,  Apfelstedt-Sylla  E,  Zrenner  E,  Lorenz  B,
Richards JE, Jacobson SG, Sieving PA, Gal A. Genetics and
phenotypes  of  RPE65  mutations  in  inherited  retinal
degeneration. Invest Ophthalmol Vis Sci 2000; 41:4293-9.
[PMID: 11095629]
21. Roepman R, Letteboer SJ, Arts HH, van Beersum SE, Lu X,
Krieger  E,  Ferreira  PA,  Cremers  FP.  Interaction  of
nephrocystin-4  and  RPGRIP1  is  disrupted  by
nephronophthisis or Leber congenital amaurosis-associated
mutations.  Proc  Natl  Acad  Sci  USA  2005;  102:18520-5.
[PMID: 16339905]
22. Henikoff S, Henikoff JG. Amino acid substitution matrices
from  protein  blocks.  Proc  Natl  Acad  Sci  USA  1992;
89:10915-9. [PMID: 1438297]
23. Perrault I, Rozet JM, Calvas P, Gerber S, Camuzat A, Dollfus
H, Châtelin S, Souied E, Ghazi I, Leowski C, Bonnemaison
M, Le Paslier D, Frézal J, Dufier JL, Pittler S, Munnich A,
Kaplan J. Retinal-specific guanylate cyclase gene mutations
in Leber's congenital amaurosis. Nat Genet 1996; 14:461-4.
[PMID: 8944027]
24. Dharmaraj SR, Silva ER, Pina AL, Li YY, Yang JM, Carter CR,
Loyer MK, El-Hilali HK, Traboulsi EK, Sundin OK, Zhu DK,
Koenekoop  RK,  Maumenee  IH.  Mutational  analysis  and
clinical  correlation  in  Leber  congenital  amaurosis.
Ophthalmic Genet 2000; 21:135-50. [PMID: 11035546]
25. Sohocki MM, Perrault I, Leroy BP, Payne AM, Dharmaraj S,
Bhattacharya SS, Kaplan J, Maumenee IH, Koenekoop R,
Meire  FM,  Birch  DG,  Heckenlively  JR,  Daiger  SP.
Prevalence  of  AIPL1  mutations  in  inherited  retinal
degenerative  disease.  Mol  Genet  Metab  2000;  70:142-50.
[PMID: 10873396]
26. Dryja TP, Adams SM, Grimsby JL, McGee TL, Hong DH, Li
T,  Andréasson  S,  Berson  EL.  Null  RPGRIP1  alleles  in
patients with Leber congenital amaurosis. Am J Hum Genet
2001; 68:1295-8. [PMID: 11283794]
27. den Hollander AI, Davis J, van der Velde-Visser SD, Zonneveld
MN, Pierrottet CO, Koenekoop RK, Kellner U, van den Born
LI, Heckenlively JR, Hoyng CB, Handford PA, Roepman R,
Cremers FP. CRB1 mutation spectrum in inherited retinal
dystrophies.  Hum  Mutat  2004;  24:355-69.  [PMID:
15459956]
28. Janecke AR, Thompson DA, Utermann G, Becker C, Hübner
CA,  Schmid  E,  McHenry  CL,  Nair  AR,  Rüschendorf  F,
Heckenlively J, Wissinger B, Nürnberg P, Gal A. Mutations
in  RDH12  encoding  a  photoreceptor  cell  retinol
dehydrogenase  cause  childhood-onset  severe  retinal
dystrophy. Nat Genet 2004; 36:850-4. [PMID: 15258582]
29. Banerjee P, Kleyn PW, Knowles JA, Lewis CA, Ross BM,
Parano  E,  Kovats  SG,  Lee  JJ,  Penchaszadeh  GK,  Ott  J,
Jacobson SG, Gilliam TC. TULP1 mutation in two extended
Molecular Vision 2008; 14:1429-1436 <http://www.molvis.org/molvis/v14/a171> © 2008 Molecular Vision
1435Dominican  kindreds  with  autosomal  recessive  retinitis
pigmentosa. Nat Genet 1998; 18:177-9. [PMID: 9462751]
30. Hagstrom SA, North MA, Nishina PL, Berson EL, Dryja TP.
Recessive  mutations  in  the  gene  encoding  the  tubby-like
protein  TULP1  in  patients  with  retinitis  pigmentosa.  Nat
Genet 1998; 18:174-6. [PMID: 9462750]
Molecular Vision 2008; 14:1429-1436 <http://www.molvis.org/molvis/v14/a171> © 2008 Molecular Vision
The print version of this article was created on 31 July 2008. This reflects all typographical corrections and errata to the article
through that date. Details of any changes may be found in the online version of the article.
1436